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ABSTRACT
Post-translational modifications control the physio-
logical activity of the signal transducer and activator
of transcription STAT1. While phosphorylation at
tyrosine Y701 is a prerequisite for STAT1 dimeriza-
tion, its SUMOylation represses the transcriptional
activity. Recently, we have demonstrated that
SUMOylation at lysine K703 inhibits the phosphory-
lation of nearby localized Y701 of STAT1. Here,
we analysed the influence of phosphorylation of
Y701 on SUMOylation of K703 in vivo. For that
reason, an Ubc9/substrate dimerization-dependent
SUMOylation (USDDS) system was developed,
which consists of fusions of the SUMOylation sub-
strate and of the SUMO-conjugating enzyme Ubc9
to the chemically activatable heterodimerization
domains FKBP and FRB, respectively. When FKBP
fusion proteins of STAT1, p53, CRSP9, FOS,
CSNK2B, HES1, TCF21 and MYF6 are coexpressed
with Ubc9-FRB, treatment of HEK293 cells with the
rapamycin-related dimerizer compound AP21967
induces SUMOylation of these proteins in vivo.
For STAT1-FKBP and p53-FKBP we show that
this SUMOylation takes place at their specific
SUMOylation sites in vivo. Using USDDS, we then
demonstrate that STAT1 phosphorylation at Y701
induced by interferon-b treatment inhibits
SUMOylation of K703 in vivo. Thus, pY701 and
SUMO-K703 of STAT1 represent mutually exclusive
modifications, which prevent signal integration at
this molecule and probably ensure the existence of
differentially modified subpopulations of STAT1
necessary for its regulated nuclear cytoplasmic
activation/inactivation cycle.
INTRODUCTION
Functions of proteins are often controlled by post-
translational modiﬁcations, such as phosphoryl-
ation, myristoylation, acetylation, ubiquitination and
SUMOylation. These modiﬁcations can be constitutively
or regulated and often prime or hinder further modiﬁca-
tions (1). Protein SUMOylation is a reversible conjuga-
tion process with strong similarity to ubiquitination
where the SUMO protein is attached in a process of
three enzymatic steps via an isopeptide bond to the
e-amino group of a lysine residue of the substrate protein.
In a fourth step, SUMOylation can be released by SUMO-
speciﬁc proteases (2). SUMOylation is involved in the
regulation of several proteins and, consequently, poten-
tially interferes with other regulatory protein modiﬁca-
tions. Interestingly, some transcription factors, such as
HSF1, GATA-1 and MEF2A, are regulated by phosphor-
ylation-dependent SUMOylation (3–5), while MEF2D,
HIC1, NF-IL-6 and SP-3 show an interplay between
SUMOylation and acetylation (6–9). Furthermore,
SUMOylation competes with IkBa ubiquitination (10)
and, as we have demonstrated recently using Ubc9
fusion-directed SUMOylation (UFDS), SUMOylation
inhibits STAT1 phosphorylation at Y701 (11).
The in vivo analysis of the interplay between diﬀerent
protein modiﬁcations mentioned above is often hampered
by the low level of the speciﬁc modiﬁcations in the
cell and by the lacking possibilities to manipulate a spe-
ciﬁc protein modiﬁcation independently of other modi-
ﬁcations. To increase the low level of SUMOylation
in vivo, we have developed Ubc9 fusion-directed
SUMOylation (UFDS) (11). However, because of the
static fusion of Ubc9 to the substrate protein of interest,
this method is not suited to study the kinetics of
SUMOylation or the sequential SUMOylation after
diﬀerent preceding modiﬁcation events. To overcome
these limitations, we now introduce the Ubc9/substrate
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Instead of a static fusion, this system makes use of a
chemically inducible interaction between Ubc9 and the
substrate of interest allowing substrate-directed
SUMOylation in vivo at a controlled time point.
USDDS now enables us to study induced SUMOylation
in dependence on other pre-existing modiﬁcations. Here,
we demonstrate USDDS with eight substrate proteins and
used USDDS to analyse the eﬀect of STAT1 phosphory-
lation at Y701 on its SUMOylation at K703.
MATERIALS AND METHODS
Plasmids
We ampliﬁed the cDNA encoding for the FKBP domain
from pC4EN-F1E and the FRB (T2098L) domain
from pC4-RHE (ARGENT Regulated Heterodimeriza-
tion Kit) by PCR using the primers FKBP-EcoRI (50-G
CGCGAATTCTCCAGAGGAGTGCAGGTGGAAAC
CATC-30) and FKBP-XbaI (50-GCGCTCTAGATTAAC
TAGTTTCCAGTTTTAGAAGCTC-30) or the primers
FRB-EcoRI (50-GCGCGAATTCTCCAGAATCCTCTG
GCATGAGATGTGG-30) and FRB-XbaI (50-GCGCTC
TAGATTAACTAGTCTTTGAGATTCGTCGGAACA
CATGATA-30) and cloned it into the EcoRI and
XbaI sites of pcDNA3 (Invitrogen) to obtain the
pcDNA3-MCS-FKBP/FRB expression vectors. We have
taken the cDNA-encoding human STAT1a from the
pcDNA3-STAT1-Ubc9 plasmid (11) by BamHI/EcoRI
digestion, and cloned it into the BamHI and EcoRI sites
of pcDNA3-MCS-FKBP/FRB to generate the mamma-
lian STAT1-FKBP/FRB expression vectors. Dependent
on an EcoRI site in the coding sequence, seven C-terminal
amino acids of the human STAT1a in the STAT1-FKBP/
FRB fusion proteins are missing. We then have taken the
cDNA coding for human p53 from the plasmid
pcDNA3-p53-Ubc9 by BamHI/EcoRI digestion, and
cloned it into the BamHI and EcoRI sites of
pcDNA3-MCS-FKBP/FRB to generate the mammalian
p53-FKBP/FRB expression vectors. For generation of
the destination vector (pcDNA3-RfB-FKBP) for fusion
of open reading frames to the N-terminus of FKBP, we
ampliﬁed the cDNA encoding the FKBP domain from
pC4EN-F1E by PCR using the primers FKBP-EcoRV
(50-GCGCGATATCTCCAGAGGAGTGCAGGTGGA
AACCATC-30) and FKBP-XhoI (50-GCGCCTCGAGTT
AACTAGTTTCCAGTTTTAGAAGCTC-30) and cloned
it into the EcoRV and XhoI sites of pcDNA3 (Invitrogen)
to obtain the pcDNA3-MCS-FKBP2 expression vector.
We then inserted the Gateway RfB recombination cas-
sette (Invitrogen) into the EcoRV site of the pcDNA3-
MCS-FKBP2. The ORF-FKBP fusion protein expression
vectors were obtained by recombination of the above
described destination vector with the ORF (Table 1) har-
bouring entry plasmids using the Gateway recombination
system (Invitrogen).
Transfection, cell lysis andwestern blotting
HEK293 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium with high glucose, complemented with
10% fetal calf serum, 2mM L-glutamine, 100U/ml peni-
cillin and 100mg/ml streptomycin. We performed trans-
fection of 50–80% conﬂuent HEK293 cells in 12-well
plates using the polyethylenimine transfection reagent
according to Christina Ehrhardt et al. (13). We grew the
transfectants for 24h, then lysed them in 150ml of gel
loading buﬀer [160mM Tris–HCL, pH 6.8, 4% (w/v)
sodium dodecyl sulphate (SDS), 20% (v/v) glycerol,
0.5% b-mercaptoethanol (v/v), 0.008% (w/v) bromophe-
nol blue] and incubated them for 10min at 958C. For
western blot analysis, we separated the proteins by SDS–
PAGE, blotted the proteins on a PVDF membrane and
detected them with speciﬁc primary antibodies [a-Ubc9
(H81, Santa Cruz), a-pY701-STAT1 (Tyr701, Cell
Signaling), a-STAT1 (Cell Signaling), a-p53 (1C12, Cell
Signaling), a-SUMO1 (Cell Signaling), a-FKBP (1-026A,
Aﬃnity Bioreagents)], a horseradish peroxidase-conju-
gated secondary antibody, the Immobilon
TM Western
(Millipore) and the LAS-3000 imaging system (Fuji).
For the interferon-stimulation experiments, we grew the
transfectants for 24h and then either stimulated them with
1000 U/ml of interferon-b or left them unstimulated for
1h. Then the cells were incubated further 0, 1, 2 or 4h in
the medium with the interferon-b without or after adding
AP21967 to a ﬁnal concentration of 1mM. Then we lysed
the cells and analysed the proteins by western blotting.
RESULTS
AP21967-dependent binding ofUbc9 tovarious substrate
proteins induces their SUMOylation
Post-translational protein modiﬁcations can act sepa-
rately, together or even counteract each other to integrate
Table 1. Comparison of protein SUMOylation by USDDS and UFDS
Potential substrate
protein
SUMOylation
in USDDS
SUMOylation
in UFDS
STAT1 + +
p53 + +
CRSP9 + +
FOS + +
CSNK2B + +
EDF1 (+/ )+
TCF21 + (+/ )
ATF3 (+/ ) (+/ )
VDRIP   
STK16   
CKS2   
RFXANK   
CDK4   (+/ )
MAPK13   (+/ )
CDKN3   (+/ )
CDKN2D   (+/ )
MYF6 +  
HES1 +  
SUMOylation of the candidate proteins chosen in this study is com-
pared with SUMOylation of the same proteins in the static UFDS
system analysed before (11,12). For USDDS, the coding sequences of
all listed genes have been fused with the C-terminus to FKBP. (+),
SUMOylation; (+/ ) weak SUMOylation; ( ) no detectable
SUMOylation.
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protein (1). To characterize the interplay of SUMOylation
with other covalent modiﬁcations in adirect andcontrolled
way, we generated an inducible USDDS system (Figure 1).
USDDS replaces the static protein fusion-immanent
properties of UFDS (11) with the ‘protein matchmaker’
approach utilizing rapamycin-induced heterodimer
formation between the 12kDa-FK506-binding protein
(FKBP12) and the 12kDa-FKBP12-rapamycin-associated
protein (FRB) which together form a relatively stable
ternary complex (14). Accordingly, we fused the appropri-
ate protein domains of FKBP and FRB, which can be
heterodimerized by the synthetic rapamycin derivative
AP21967 (15), to Ubc9 and the SUMOylation substrate
of interest, respectively.
As proteins of interest we have chosen STAT1 and, the
tumour suppressor protein p53, which displays signiﬁcant
SUMOylation in vivo (16–19). To generalize the approach,
we also analysed three SUMOylation substrates identiﬁed
previously by UFDS and veriﬁed without Ubc9 fusion,
CRSP9, FOS and CSNK2B (12), as well as further poten-
tial nuclear proteins and SUMOylation substrates in
USDDS (summarized in Table 1). All fusion proteins
were expressed in HEK293 cells to detectable levels
(Figure 2A–J and data not shown). When p53-FRB or
STAT1-FRB were coexpressed with Ubc9-FKBP together
with EGFP-SUMO1, no signiﬁcant EGFP-SUMOylation
of STAT1-FRB and of p53-FRB could be detected
(Figure 2A and B). In contrast, incubation of the
transfected cells with the dimerizer AP21967 leads to a
strongly enhanced SUMOylation of STAT1-FRB and
p53-FRB already after 1h, which reaches saturation
after 2–4h (Figure 2A and B). The estimated stoichio-
metry of the SUMOylation of STAT1 and p53 in
USDDS is similar to that of UFDS. However, USDDS
clearly functions in an inducible manner. We also tested
STAT1-FKBP, p53-FKBP and FKBP fusions of the
proteins listed in Table 1 in combination with
Ubc9-FRB. Again, we found an even slightly stronger,
AP21967-induced SUMOylation of the STAT1- and
p53-FKBP fusion proteins (Figure 2C and D).
Furthermore, we found AP21967-induced SUMOylation
of the CRSP9-FKBP, FOS-FKBP, TCF21-FKBP,
CSNK2B-FKBP, MYF6-FKBP and HES1-FKBP
(Figure 2E–J). Overall, the results by the USDDS system
summarized in Table 1 resemble the data obtained using
the UFDS system. However, there are clear diﬀerences in
SUMOylatability at least for HES1 or MYF6, which are
SUMOylated in USDDS only. These diﬀerences could
result from structural constrains of the static UFDS
system, which are not present in the more ﬂexible
USDDS approach.
USDDS targetsthespecific SUMOylation sites
To prove that USDDS displays speciﬁcity for the
in vivo SUMOylation sites of p53 and STAT1, we coex-
pressed the mutant proteins p53K386R-FRB and
STAT1K703R-FRB with Ubc9-FKBP and EGFP-
SUMO1. In HEK293 cells, we could not identify any
SUMOylation of STAT1K703R-FRB (Figure 3A) but
only weak second site SUMOylation of p53K386R-FRB
(Figure 3B) which was also detected with the UFDS
system (11). Obviously, the induced heterodimerization
of the Ubc9 fusion protein with the substrate fusion pro-
teins leads preferentially to a modiﬁcation at their speciﬁc
SUMOylation sites. This let us suppose that USDDS is a
useful tool to analyse the dynamic interplay between
SUMOylation and other protein modiﬁcations.
USDDS demonstrates that pY701 excludes K703
SUMOylation of STAT1
It has been shown that interferon-g stimulation of
STAT1-transfected COS7 cells, a treatment which also
increases STAT1 phosphorylation (20), leads to an
enhanced SUMOylation of STAT1 (21,22). This let us
postulate that STAT1 phosphorylation at Y701 might
directly enhance the SUMOylatability of STAT1 at
K703. Using UFDS, we have already demonstrated that
STAT1 SUMOylation at K703 inhibits Y701 phosphory-
lation (11), but it was not possible to study the opposite
eﬀect by UFDS (data not shown), possibly due to the
static SUMOylation of STAT1 in this experimental set-
ting. Because of that, we now used USDDS to study the
eﬀect of STAT1 phosphorylation at Y701 on K703
SUMOylation in vivo (Figure 4). Therefore, we ﬁrst coex-
pressed STAT1-FRB, Ubc9-FKBP and EGFP-SUMO1 in
HEK293 cells. After 24h, we stimulated the cells with
interferon-b for 1h to induce STAT1 phosphorylation
and subsequently incubated the cells with 1mM AP21967
Figure 1. Schematic representation of the USDDS. The SUMOylation
substrate of choice is fused to one of the heterodimerization domains
(FRB) and Ubc9 to the other (FKBP). When the fusion proteins are
coexpressed in HEK293 cells, incubation with the membrane permeable
compound AP21967 induces heterodimerization of the two fusion pro-
teins. As a result, the SUMO-loaded conjugating enzyme Ubc9 is
brought in close proximity to the substrate of interest and eﬀective
SUMO conjugation of the substrate occurs.
PAGE 3 OF 7 Nucleic AcidsResearch, 2009, Vol.37,No. 4 e30Figure 2. AP21967-induced in vivo SUMOylation of STAT1 and p53. (A) STAT1-FRB and EGFP-SUMO1 or (B) p53-FRB and EGFP-SUMO1
were cotransfected into HEK293 cells either alone ( ) or together with Ubc9-FKBP (+). (C) STAT1-FKBP and EGFP-SUMO1 or (D) p53-FKBP
and EGFP-SUMO1 or (E) CRSP9-FKBP and EGFP-SUMO1 or (F) TCF21-FKBP and EGFP-SUMO1 or (G) FOS-FKBP and EGFP-SUMO1 or
(H) CSNK2B-FKBP and EGFP-SUMO1 or (I) MYF6-FKBP and EGFP-SUMO1 or (J) HES1-FKBP and EGFP-SUMO1 were cotransfected
into HEK293 cells either alone ( ) or together with Ubc9-FRB (+). After 24h, the cells were stimulated with the AP21967 (1mM) for the indicated
times. Fusion proteins in the extracts of the transfectants were detected by western blot using (A and C) a STAT1 antibody (a-STAT1), (B and D)
a p53 antibody (a-p53) or (E–J) a FKBP antibody (a-FKBP). E-S1-STAT1-FRB(FKBP)=STAT1-FRB(FKBP) fusion protein conjugated
with coexpressed EGFP-SUMO1; E-S1-p53-FRB(FKBP)=p53-FRB(FKBP) conjugated with coexpressed EGFP-SUMO1; E-S1-CRSP9-
FKBP=CRSP9-FKBP conjugated with coexpressed EGFP-SUMO1; E-S1-TCF21-FKBP=TCF21-FKBP conjugated with coexpressed EGFP-
SUMO1; E-S1-FOS-FKBP=FOS-FKBP conjugated with coexpressed EGFP-SUMO1; E-S1-CSNK2B-FKBP=CSNK2B-FKBP conjugated with
coexpressed EGFP-SUMO1; E-S1-MYF6-FKBP=MYF6-FKBP conjugated with coexpressed EGFP-SUMO1; E-S1-HES1-FKBP=HES1-FKBP
conjugated with coexpressed EGFP-SUMO1; and E=EGFP-Tag.
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tion of STAT1-FRB with Ubc9-FKBP. The transfectants
were lysed after diﬀerent incubation times and the proteins
were analysed by a pY701-STAT1 speciﬁc antibody that
recognizes the tyrosine 701 phosphorylation also in
SUMOylated STAT1 (11) (Figure 4A). It can be seen
that interferon-b stimulation induced Y701 phosphoryla-
tion of endogenous STAT1 and of the STAT1-FRB fusion
protein. However, pY701 could not be detected in the gel
region where SUMOylated STAT1-FRB migrates, neither
after 1h nor 2h or 4h of interferon-b stimulation. A sub-
sequent western blot using a STAT1 speciﬁc antibody
clearly detects SUMOylated STAT1-FRB after 1, 2 and
4h incubation with AP21967. Hence, STAT1 phosphory-
lation at Y701 excludes K703 SUMOylation.
Y701 phosphorylationand K703SUMOylation are mutually
exclusive
The results obtained by UFDS (11) and USDDS (above)
let us suppose that Y701 phosphorylation and K703
SUMOylation are mutually exclusive modiﬁcations. To
further characterize the dynamic interplay between Y701
phosphorylation and K703 SUMOylation of STAT1 by
USDDS in vivo, we applied USDDS to analyse the inﬂu-
ence of K703 SUMOylation on Y701 phosphorylation of
both STAT1-FRB and STAT1-FKBP (Figure 4B and C)
and extended to analysis of the inﬂuence of Y701 phos-
phorylation on K703 SUMOylation on STAT1-FKBP
(Figure 4C). Therefore, we transfected HEK293 cells
with the respective expression plasmids and stimulated
the transfectants ﬁrst with interferon-b and then with
AP21967, or vice versa. Western blot analysis of the trans-
fectants for the STAT1-FRB (Figure 4B) or
STAT1-FKBP (Figure 4C) revealed that no double
modiﬁcation of STAT1 by SUMOylation and Y701 phos-
phorylation is detectable under any of the stimulation sce-
narios although single Y701 phosphorylation or
SUMOylation are clearly detectable. Hence, STAT1 is
phosphorylated at Y701 or SUMOylated at K703 but
cannot carry both modiﬁcations at the same time.
A closer inspection of the blots also shows a weak
decrease in the pY701 signal of STAT1-FRB and
STAT1-FKBP when the cells were stimulated ﬁrst with
interferon-b and then with AP21967 (Figure 4A and B,
P-STAT1-FRB; Figure 4C, P-STAT1-FKBP). This is pos-
sibly due to the kinetics of the interferon-b stimulation in
HEK293 where the induced tyrosine 701 phosphorylation
declines after about 2h of stimulation. Furthermore,
SUMOylation of STAT1-FRB (FKBP) could reduce the
amount of protein that can be re-phosphorylated at Y701.
Apart from this, we cannot completely rule out that there
is also an eﬀect of AP21967 on dephosphorylation or deg-
radation of pY701-STAT1-FRB. However, USDDS
clearly reveals that STAT1 SUMOylation at K703 and
STAT1 phosphorylation at Y701 are mutually exclusive
while interferon-b stimulation does not inhibit overall
SUMOylation in the cell (Figure 4).
DISCUSSION
In the control of protein function, post-translational pro-
tein modiﬁcations can act separately, together or even
counteract each other to integrate extracellular signals
and to ensure a speciﬁc function of a protein at the appro-
priate localization within the cell (1). Here, we have char-
acterized the dynamic interplay between Y701
phosphorylation and K703 SUMOylation of STAT1 by
USDDS. The results obtained together with the ﬁnding
Figure 3. USDDS results in SUMOylation of STAT1 and p53 at their speciﬁc SUMOylation sites. EGFP-SUMO1 and (A) STAT1-FRB or STAT1-
K703R-FRB, (B) p53-FRB or p53-K386R-FRB were coexpressed in HEK293 cells either alone ( ) or together with Ubc9-FKBP (+). After 24h, the
cells were stimulated with AP21967 (1mM) for the indicated times. Fusion proteins in the extracts of the transfectants were detected by western blot
using (A) a STAT1 antibody (a-STAT1) or (B) a p53 antibody (a-p53). After stripping the Ubc9-FKBP was detected with the Ubc9 antibody
(a-Ubc9) and after a second stripping EGFP-SUMO1 and SUMOylated proteins (EGFP-S1 proteins) were detected with the SUMO1 antibody
(a-SUMO1). E-S1-STAT1-FRB=STAT1-FRB fusion protein conjugated with coexpressed EGFP-SUMO1; E-S1-p53-FRB=p53-FRB conjugated
with coexpressed EGFP-SUMO1; and E=EGFP-Tag.
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phorylation at Y701 (11) support a model where phos-
phorylation of tyrosine 701 und SUMOylation of lysine
703 of STAT1 represent mutually exclusive modiﬁcations
which prevent signal integration at these molecule
and probably ensure the existence of diﬀerentially modi-
ﬁed subpopulations of STAT1, pY701-STAT1 and
SUMO-K703-STAT1, necessary for its regulated nuclear
cytoplasmic activation/inactivation cycle (Figure 4D).
pY701-STAT1 dimerizes, translocates to the nucleus
and becomes part of the transcriptional initiation complex
at STAT1-speciﬁc genes. Generation of SUMO-
K703-STAT1 possibly takes place in the nucleus after
dephosphorylation of STAT1 and could be necessary to
inhibit a fast re-phosphorylation of STAT1 directly in the
nucleus before it is exported to the cytoplasm. Hence, a
second round of STAT1 transcriptional activation can
only begin in the cytoplasm. We can also not exclude
that the two diﬀerently modiﬁed STAT1 populations,
pY701-STAT1 and SUMO-K703-STAT1, are essential
components of diﬀerent transcriptional complexes at
diﬀerent subsets of genes. Accordingly, generation
of SUMO-K703-STAT1 after dephosphorylation of
pY701-STAT1 in the nucleus could lead to transcriptional
reprogramming where SUMOylation could also act as
prerequisite for further modiﬁcations such as acetylation
(23). Apart from this, it is possible that the STAT1
SUMOylation takes place in the cytoplasm, where it
could inhibit the Y701 phosphorylation or is involved in
an alternative nuclear import. USDDS will be probably
helpful in answering these open questions in further stu-
dies, where a detailed characterization of the functional
properties of the overexpressed STAT1 fusion proteins
will be also required.
Figure 4. Mutually exclusive in vivo phosphorylation of Y701 and SUMOylation of K703 in STAT1. (A–C) For USDDS, STAT1-FRB or STAT1-
FKBP was coexpressed with Ubc9-FKBP or Ubc9-FRB and EGFP-SUMO1 in HEK293 cells. After 24h, the transfectants were stimulated with
interferon-b (1/2h or 1h) or left unstimulated (–) and were subsequently treated with AP21967 (1mM). (B and C) Where indicated transfectants were
treated (2h) with AP21967 (1mM) ﬁrst and subsequently stimulated with interferon-b (1h). The proteins of the transfectants were immunoblotted
with a phospho (p)Y701 STAT1 antibody (a-pY701 STAT1), stripped and re-probed with a STAT1 antibody (a-STAT1) to detect also non-
phosphorylated and SUMOylated STAT1. (D) Schematic representation of the role of mutually exclusive STAT1 modiﬁcations. The phosphorylation
site Y701 of STAT1 and the SUMOylation site K703 are in close proximity. Receptor activation, e.g. by interferon-b induces phosphorylation at
Y701. This is a prerequisite for the STAT1 dimerization, nuclear import and transcriptional activation and inhibits SUMOylation at K703. STAT1 is
inactivated by a nuclear phosphatase (PPase). Dephosphorylated STAT1 is then a potential substrate for SUMOylation that inhibits nuclear
re-phosphorylation of Y701 of STAT1 and is possibly involved in transcriptional reprogramming, nuclear export or regulation of further STAT1
modiﬁcations such as acetylation. SUMOylation of cytoplasmic STAT1 inhibits Y701 phosphorylation and could be involved in nuclear import and
regulation of preceding STAT1 modiﬁcations like acetylation. E-S1-STAT1-FRB or -FKBP=STAT1-FRB or -FKBP fusion protein conjugated
with coexpressed EGFP-SUMO1, P-STAT1-FRB or -FKBP=STAT1-FRB or -FKBP phosphorylated at Y701, E=EGFP-Tag. E-S1-STAT1-FRB
or -FKBP, P-STAT1-FRB or -FKBP, endogenous P-STAT1, STAT1-FRB or -FKBP and endogenous STAT1 are indicated by black arrow heads.
In the upper blot, the open arrow head indicates the positions of the E-S1-STAT1-FRB or -FKBP that are not decorated by the pY701-STAT1
antibody (a-pY701-STAT1).
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show a reduced SUMOylation of a STAT1 pY701-peptide
in vitro (24) and are apparently in contrast to the described
enhancement of STAT1 SUMOylation by interferon-g
stimulated phosphorylation of STAT1. However, very
recently an interferon-g induced STAT1 phosphorylation
of S727 by the MKK6/p38 pathway has been described,
which enhances SUMOylation at K703 (25). Hence, the
intriguing possibility exists that, depending on the phos-
phorylated site, STAT1 K703 SUMOylation can be stimu-
lated or inhibited oﬀering the possibility for a complex
regulation.
The analysis of the interplay of diﬀerent modiﬁcations
at one protein will be one of the diﬃcult tasks to be solved
in future description of signalling processes. We have
developed the USDDS system that combines the eﬀective
and speciﬁc SUMOylation of UFDS with an inducible
heterodimerization that makes it possible to reach con-
trolled SUMOylation of a substrate protein at any time
point within a sequential scenario of modiﬁcation events.
Although we can not exclude some forced artiﬁcial
SUMOylation by the USDDS, we have demonstrated
that this is a unique method for studying the kinetics
and the dynamic interplay of protein SUMOylation with
other post-translational modiﬁcations.
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